Potassium Cation
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Potassium Cation: From an Unspecified Original Indication to Hypertensive Disorder
One-Sentence Summary
Potassium cation is a generic ion/nutrient entry rather than a defined drug product, and no original approved indication is recorded for it in the data compiled for this report. The TxGNN model predicts it may be effective for hypertensive disorder, with a very high score (99.2%). However, there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded (the only US license has no approved indication text) |
| Predicted New Indication | Hypertensive disorder |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L5 |
| US Market Status | Cancelled only |
| Number of NDAs | 1 (cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Potassium cation is not a defined drug product, and its original indication is not documented in the data compiled for this report, so a direct link between an original and a new indication cannot be drawn.
Biologically, higher dietary potassium intake is associated with lower blood pressure through increased sodium excretion (natriuresis), vasodilation and reduced sympathetic tone. This makes the hypertension prediction plausible. However, this reasoning comes from general background knowledge, not from trials or literature in the compiled data. Any repurposing claim would need to be tested on specific potassium salt formulations.
Other predicted indications are weaker still:
| Rank | Predicted Indication | TxGNN Score | Comment |
|---|---|---|---|
| 2 | Pulmonary hypertension owing to lung disease and/or hypoxia | 99.15% | Potassium channel biology is involved in hypoxic pulmonary vasoconstriction, but that is not the same as potassium supplementation |
| 3 | Pulmonary hypertension with unclear multifactorial mechanism | 99.15% | Identical score to rank 2, suggesting a shared graph neighborhood rather than independent evidence |
| 4 | Malignant hypertensive renal disease | 99.11% | Hyperkalemia risk in renal impairment likely outweighs any speculative benefit |
| 5 | Malignant renovascular hypertension | 99.11% | Potassium disturbances here are complications to correct, not a disease-modifying mechanism |
| 6 | Braddock syndrome | 99.01% | Very rare condition; no plausible mechanistic link evident |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Not available | Sore Throat 911 (DelCorean, LLC) | Lotion | Not stated (license cancelled) |
Safety Considerations
Please refer to the package insert for safety information.
No drug interaction records were found. In the renal-related predictions (ranks 4 and 5), hyperkalemia from potassium supplementation is a clinically important concern in patients with renal impairment.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but the evidence level is L5 (model prediction only), with no trials, no literature, no mechanism data and no active US license. Potassium cation is a generic entry rather than a specific product, so the prediction cannot yet be turned into a testable drug candidate.
To proceed, the following is needed:
- Selection of specific potassium salt formulations (e.g., potassium chloride, potassium citrate) to evaluate
- Package insert warnings and contraindications, which are currently missing and block safety screening
- Mechanism of action data
- A systematic literature search on potassium intake or supplementation and blood pressure, including any existing trials and meta-analyses
- A renal-safety and hyperkalemia risk assessment, especially before considering any renal-related hypertensive indication
- Route-of-administration compatibility assessment, since the only past US product was a topical lotion
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.